
Video unavailable
This video can't be played right now.
Immunotherapy updates in head and neck cancer from ASCO 2026
On this week’s episode of VJOncology podcasts, we bring you head and neck cancer highlights in immuno-oncology from the 2026 ASCO Annual Conference. Join Barbara Burtness from the Yale School of Medicine, Hannah Kenny from Thomas Jefferson University Hospital, Ari Rosenberg from the University of Chicago, Nabil Saba from Emory University, and Kedar Kirtane from Moffitt Cancer Center as they discuss highlights from the meeting. They explore new data from key trials including OrigAMI-4, EV-202 and KEYNOTE-412, as well as emerging cellular therapies and checkpoint inhibitors.
Suggested videos

Key advances in head and neck cancer from ASCO 2026
VJOncology · 2:49

Phase I trial of ICV-delivered bivalent CAR T-cells in glioblastoma
VJOncology · 2:46

ASCO 2026 Head & Neck AND Sarcoma Highlights – Drs. Samantha Armstrong & Ari Rosenberg
OncBrothers: Practice-Changing Cancer Discussions · 25:30

What is the future role of ctDNA as a biomarker in colorectal cancer?
VJOncology · 2:07

Integrating HPV-specific immunotherapy into head and neck cancer care
VJOncology · 0:48

iwCAR-T 2026: advances in TIL therapy for solid tumors
VJOncology · 19:20

A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
VJOncology · 1:05

Safety and efficacy outcomes of SMART-based SABR in ultracentral NSCLC
VJOncology · 1:23

Prof Kevin Harrington, 'New treatment options in Adenoid Cystic Carcinoma: update from ASCO 2026'
Salivary Gland Cancer UK · 14:14

Updates in surgical oncology at ESSO 45
VJOncology · 19:21

Best of ASCO Anchorage 2026: Dr Aditya Shreenivas, MD
Total Health Oncology · 1:05

Reprogramming the tumor microenvironment: targeting acidity to unlock antitumor immunity
VJOncology · 11:53